Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "Goa"

1086 News Found

Vetter advances next-gen syringe closure system towards 2027 launch
Medical Device | January 16, 2026

Vetter advances next-gen syringe closure system towards 2027 launch

The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats


Max Healthcare teams up with Google to enable direct appointment bookings
Hospitals | January 15, 2026

Max Healthcare teams up with Google to enable direct appointment bookings

The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide


Thermo Fisher and NVIDIA team up to supercharge labs with AI
Digitisation | January 14, 2026

Thermo Fisher and NVIDIA team up to supercharge labs with AI

Artificial intelligence coupled with laboratory automation will transform how scientific work is performed


Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
News | January 11, 2026

Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing

The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients


Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy
News | January 11, 2026

Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy

The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab


NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
Clinical Trials | January 11, 2026

NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial

The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases


InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
Biopharma | January 11, 2026

InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway

InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development